Cargando…

High claudin-4 antigen expression in triple-negative breast cancer by the immunohistochemistry method

BACKGROUND: Triple-negative breast cancer is a heterogeneous subtype of breast cancer. Claudin is an epithelial tight junctional protein, and also it is a receptor for clostridium perfringens enterotoxin and shows impairment of expression in several cancers. The chief purpose of this study is to ass...

Descripción completa

Detalles Bibliográficos
Autores principales:	Naimi, Azar, Zare, Nadereh, Amjadi, Elham, Soltan, Maryam
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8995311/ https://www.ncbi.nlm.nih.gov/pubmed/35419062 http://dx.doi.org/10.4103/jrms.jrms_1389_20

Ejemplares similares

Androgen Receptor Expression and Its Correlation with Clinicopathological Parameters in Iranian Patients with Triple Negative Breast Cancer
por: Naimi, Azar, et al.
Publicado: (2020)

Targeting PVT1 Exon 9 Re-Expresses Claudin 4 Protein and Inhibits Migration by Claudin—Low Triple Negative Breast Cancer Cells
por: Levine, Fayola, et al.
Publicado: (2021)

Diagnostic Value of Claudin-4 and EZH2 Immunohistochemistry in Effusion Cytology
por: Elhosainy, Aliaa, et al.
Publicado: (2022)

All Benign and Malignant Apocrine Breast Lesions Over-Express Claudin 1 and 3 and Are Negative for Claudin 4
por: Shousha, Sami, et al.
Publicado: (2019)

Detection of Increased Expression of Claudin-1 in Triple-Negative Breast Cancer: Analysis and Clinical-Pathological Correlation
por: Ouban, Abderrahman, et al.
Publicado: (2023)

High-level cytoplasmic claudin 3 expression is an independent predictor of poor survival in triple-negative breast cancer
por: Jääskeläinen, Anniina, et al.
Publicado: (2018)

Twist1 accelerates tumour vasculogenic mimicry by inhibiting Claudin15 expression in triple‐negative breast cancer
por: Zhang, Danfang, et al.
Publicado: (2020)

Novel immunohistochemistry-based signatures to predict metastatic site of triple-negative breast cancers
por: Klimov, Sergey, et al.
Publicado: (2017)

Immunohistochemistry-based molecular subtyping of triple-negative breast cancer and its prognostic significance
por: Leeha, Marisa, et al.
Publicado: (2023)

HER3 targeting augments the efficacy of panobinostat in claudin-low triple-negative breast cancer cells
por: Lyu, Hui, et al.
Publicado: (2023)

Immunohistochemistry for Claudin-4 and BAP1 in the Differential Diagnosis between Sarcomatoid Carcinoma and Sarcomatoid Mesothelioma
por: Zuccatosta, Lina, et al.
Publicado: (2023)

Panobinostat suppresses the mesenchymal phenotype in a novel claudin-low triple negative patient-derived breast cancer model
por: Matossian, Margarite D., et al.
Publicado: (2018)

MYC regulates fatty acid metabolism through a multigenic program in claudin-low triple negative breast cancer
por: Casciano, Jessica C., et al.
Publicado: (2020)

CYP1B1 Augments the Mesenchymal, Claudin-Low, and Chemoresistant Phenotypes of Triple-Negative Breast Cancer Cells
por: Hollis, Paul R., et al.
Publicado: (2022)

Prognostic Role of Claudin-1 Immunohistochemistry in Malignant Solid Tumors: A Meta-Analysis
por: Pyo, Jung-Soo, et al.
Publicado: (2019)

HER3 Differentiates Basal From Claudin Type Triple Negative Breast Cancer and Contributes to Drug and Microenvironmental Induced Resistance
por: Sinevici, Nicoleta, et al.
Publicado: (2020)

Comment on “Prognostic Role of Claudin-1 Immunohistochemistry in Malignant Solid Tumors: A Meta-Analysis”
por: Wang, Bolin, et al.
Publicado: (2019)

Nanobodies; new molecular instruments with special specifications for targeting, diagnosis and treatment of triple-negative breast cancer
por: Bakherad, Hamid, et al.
Publicado: (2022)

The prognostic value of a combined immune score in tumor and immune cells assessed by immunohistochemistry in triple-negative breast cancer
por: Choi, Ji Eun, et al.
Publicado: (2023)

Response to Comment on “Prognostic Role of Claudin-1 Immunohistochemistry in Malignant Solid Tumors: A Meta-Analysis”
por: Pyo, Jung-Soo, et al.
Publicado: (2019)

Anti-GBM disease with positive serum anti-GBM antibodies but negative IgG deposition: A case report
por: Kazemzadeh, Kimia, et al.
Publicado: (2023)

PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel–Treated Advanced Triple-Negative Breast Cancer
por: Rugo, Hope S, et al.
Publicado: (2021)

Programmed Death Ligand 1 Immunohistochemistry in Triple-Negative Breast Cancer: Evaluation of Inter-Pathologist Concordance and Inter-Assay Variability
por: Ahn, Soomin, et al.
Publicado: (2021)

Targeting claudin‐4 enhances chemosensitivity in breast cancer
por: Luo, Yi, et al.
Publicado: (2020)

Regulation of the Epithelial-Mesenchymal Transition by Claudin-3 and Claudin-4
por: Lin, Xinjian, et al.
Publicado: (2013)

Tissue Expression Of LPHN3 in Breast Cancer: An Immunohistochemistry Method
por: Kotepui, Kwuntida Uthaisar, et al.
Publicado: (2020)

Immune Biomarkers in Triple-Negative Breast Cancer: Improving the Predictivity of Current Testing Methods
por: Porta, Francesca Maria, et al.
Publicado: (2023)

Evaluation of GATA3 and GCDFP15 Expression in Triple Negative Breast Cancers
por: Ahadi, Mahsa, et al.
Publicado: (2023)

Cancer testis antigen expression in triple negative breast cancer: Candidate targets for cancer immunotherapy?
por: Hendrickx, Wouter, et al.
Publicado: (2015)

Trophoblast cell-surface antigen 2 (TROP2) expression in triple-negative breast cancer
por: Jeon, Yeonjin, et al.
Publicado: (2022)

Biological Landscape of Triple Negative Breast Cancers Expressing CTLA-4
por: Navarrete-Bernal, María G. C., et al.
Publicado: (2020)

Claudin 1 in Breast Tumorigenesis: Revelation of a Possible Novel “Claudin High” Subset of Breast Cancers
por: Myal, Yvonne, et al.
Publicado: (2010)

Immunohistochemistry Heterogeneity in Reported Breast Cancer Demographics From India: Triple-Negative Breast Cancer Rates Could Be Lower Than Suggested in Pooled Meta-Analysis
por: Chatterjee, Sanjoy, et al.
Publicado: (2016)

Interassay and interobserver comparability study of four programmed death-ligand 1 (PD-L1) immunohistochemistry assays in triple-negative breast cancer
por: Noske, Aurelia, et al.
Publicado: (2021)

Localization of Claudin‐3 and Claudin‐4 within the Small Intestine of newborn piglets
por: Deluco, Brodie, et al.
Publicado: (2021)

Correlation analysis of circulating tumor cells and Claudin-4 in breast cancer
por: Chai, Jie, et al.
Publicado: (2023)

Triple-Negative Breast Cancer
por: Chu, Quyen D., et al.
Publicado: (2012)

Triple-negative breast cancer
por: Chacón, Reinaldo D, et al.
Publicado: (2010)

Prognostic value of ERBB4 expression in patients with triple negative breast cancer
por: Kim, Ji-Yeon, et al.
Publicado: (2016)

On the Therapeutic Potential of ERK4 in Triple-Negative Breast Cancer
por: Boudghene-Stambouli, Fadia, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_tuc2g5n78no71eh14g9d7lvc6c